Advertisement

Therapeutic Potential of Melatonin in Immunodeficiency States, Viral Diseases, and Cancer

  • George J. M. Maestroni
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 467)

Abstract

Maintenance of health depends on the ability to respond appropriately to environmental Stressors via reciprocal interactions between the body and the brain. In this context, it is well recognized that the pineal hormone melatonin (MLT) plays an important role. T-helper cells bear G-protein-coupled MLT cell membrane receptors and, perhaps, MLT nuclear receptors. Activation of MLT receptors enhances the release of T-helper cell cytokines, such as γ-interferon and interleukin-2 (IL-2), as well as activation of novel opioid cytokines which crossreact immunologically with both interleukin-4 and dynorphin B. MLT has been reported also to enhance the production of interleukin-1, interleukin-6 and interleukin-12 in human monocytes. These mediators may counteract secondary immunodeficiences, protect mice against lethal viral and bacterial diseases, synergize with IL-2 against cancer and influence hematopoiesis. Hematopoiesis is influenced by MLT-induced-opioids (MIO) acting on kappa 1-opioid receptors present on bone marrow macrophages. Clinically, MLT could amplify the anti-tumoral activity of low dose IL-2, induce objective tumor regression, and prolong progression-free time and overall survival. MLT seems to be required for the effectiveness of low dose IL-2 in those neoplasias that are generally resistant to IL-2 alone. Similar findings were obtained in a study in which MLT was combined with γ-interferon in metastatic renal cell carcinoma. In addition, MLT in combination with low-dose IL-2 was able to neutralize the surgery-induced lymphocytopenia in cancer patients. IL-2 treatment in patients results in activation of the immune system and creates the most suitable biological background for MLT. The finding that MLT stimulates IL-12 production from human monocytes only if incubated in presence of IL-2 further supports this concept. On the other hand, high concentrations of MLT have been found in human breast cancer tissue. The MLT concentration, which was 3 orders of magnitude higher than that present in the plasma, correlated positively with good prognostic markers such as estrogen receptor status and nuclear grade. Whether this relates to the imunoneuroendocrine action of MLT remains to be established. Clinical studies are needed on the effect of MLT in combination with IL-2 or other cytokines in cancer patients and viral diseases including HIV-infected patients.

Keywords

Pineal Gland Metastatic Renal Cell Carcinoma Nuclear Grade Estrogen Receptor Status Lewis Lung Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anwar, M.M., Mahfouz, H.A., and Sayed, A.S., 1998, Potential protective effects of melatonin on bone marrow of rats exposed to cytotoxic drugs, Comp. Biochem. Physiol. 119:493–591.Google Scholar
  2. Banks, R.E., Patel, P.M., and Selby, P.J., 1995, Interleukin-12: a new player in cytokine therapy, Br. J. Cancer 71:655–659.Google Scholar
  3. Bartsch, C. and Bartsch, H., 1993, Melatonin secretion in oncological patients: current results and methodological considerations, in: Advances in Pineal Research 7 (G.J.M. Maestroni and A.R.J. Reiter, eds.), pp. 283–301, John Libbey, London.Google Scholar
  4. Becker, J., Veit, G., Handgretinger, R., Attanasio, G., Bruchett, G., Trenner, I., Niethammer, D., and Gupta, D., 1988, Circadian variations in the immunomodulatory role of the pineal gland, Neuroendocrinol. Lett. 10:65–80.Google Scholar
  5. Ben-Nathan, D., Maestroni, G.J.M., and Conti, A., 1995, Protective effect of melatonin in mice infected with encephalitis viruses, Arch. Virol. 140:223–230.PubMedCrossRefGoogle Scholar
  6. Ben-Nathan, D., Maestroni, G.J.M., and Conti, A., 1996, Protective effect of melatonin in viral and bacterial infections, Abstract, 2nd Locarno Meeting on Neuroendocrinoimmunology. Therapeutic potential of the Pineal Hormone Melatonin, May 5-8, Locarno, Switzerland.Google Scholar
  7. Blask, D.E., 1984, The pineal: an oncostatic gland?, in: The Pineal Gland (R.J. Reiter, ed.), pp. 253–285, Raven Press, New York.Google Scholar
  8. Blask, D.E., 1993, Melatonin in oncology, in: Melatonin. Biosynthesis, Physiological Effects, and Clinical Applications (H.-S. Yu and R.J. Reiter, eds.), pp. 447–477, CRC Press, Boca Raton.Google Scholar
  9. Bonilla, E., Valerofuenmajor, N., Pons, H., and Chacin-Bonilla, L., 1997, Melatonin protects mice infected with Venezuelan equine encephalomyelitis virus, Cell Mol. Life Sci. 53:430–434.PubMedCrossRefGoogle Scholar
  10. Carlberg, C. and Wiesenberg, I., 1995, The orphan receptor family RZR/ROR, melatonin and 5-lipoxygenase: an unexpected relationship, J. Pineal Res. 18:171–178.PubMedCrossRefGoogle Scholar
  11. Caroleo, M.C., Frasca, D., Nistico, G., and Doria, G., 1992, Melatonin as immunomodulator in immunodeficient mice, Immunopharmacology 23:81–89.PubMedCrossRefGoogle Scholar
  12. Champney, T.H. and McMurray, D.N., 1991, Spleen morphology and lymphoproliferative activity in short photoperiod exposed hamsters, in: Role of melatonin and pineal peptides in neuroimmunomodulation (F. Fraschiniand and R.J. Reiter, eds.), pp. 219–225, Plenum Publ Co, London.CrossRefGoogle Scholar
  13. Colombo, L.L., Chen, G.-J., Lopez, M.C., and Watson, R.R., 1992, Melatonin induced increase in gammainterferon production by murine splenocytes, Immunol. Lett. 33:123–126.PubMedCrossRefGoogle Scholar
  14. Conti, A., Haran-Ghera, N., and Maestroni, G.J.M., 1992, Role of pineal melatonin and melatonin-induced immuno-opioids in murine leukemogenesis, Med. Oncol. Tumor Pharmacoth. 9:87–92.Google Scholar
  15. Conti, A. and Maestroni, G.J.M., 1995, The clinical neuroimmunotherapeutic role of melatonin in oncology, J. Pineal Res. 19:103–110.PubMedCrossRefGoogle Scholar
  16. Del Gobbo, V., Libri, V., Villani, N., Caliò, R., and Nstico, G., 1989, Pinealectomy inhibits interleukin-2 production and natural killer activity in mice, Int. J. Immunopharmacol. 11:567–577.PubMedCrossRefGoogle Scholar
  17. Del Prete, G., Maggi, E., and Romagnani, S., 1994, Human Thl and Th2 cells: Functional properties, mechanisms of regulation and role in disease, Lab. Invest. 70:299–307.PubMedGoogle Scholar
  18. Garcia-Mauriño, S., Gonzales-Haba, M.G., Calvo, J.R., Rafii-El-Idrissi, M., Sanchez-Margalet, V., Goberna, R., and Guerrero, J.M., 1997, Melatonin enhances IL-2, 11-6, and IFN-γ production by human circulating CD4+ cells., J. Immunol. 159:574–581.PubMedGoogle Scholar
  19. Garcia-Perganeda, A., Pozo, D., Guerrero, J.M., and Calvo, J.R., 1997, Signal transduction for melatonin in human lymphocytes. Involvement of a pertussis toxin-sensitive G protein, J. Immunol. 159:3774–3781.PubMedGoogle Scholar
  20. Giordano, M. and Palermo, M.S., 1991, Melatonin-induced enhancement of antibody dependent cellular cytotoxicity, J. Pineal Res. 10:117–121.PubMedCrossRefGoogle Scholar
  21. Guerrero, J.-M., Garcia-Maurino, S., Gil-Haba, M., Rafii-El-Idrissi, M., Pozo, D., Garcia-Perganeda, A., and Calvo, J.R., 1996, Mechanisms of action on the human immune system: Membrane receptors versus nuclear receptors, in: Therapeutic potential of the Pineal Hormone Melatonin, vol. 23 (G.J.M. Maestroni, A. Conti, and R.J. Reiter, eds.), Frontiers of Hormone Research, p. 43–52, Karger, Basal.Google Scholar
  22. Haldar, C., Haussler, D., and Gupta, D., 1992, Response of CFU-GM (colony forming units for granulocytes and macrophages) from intact and pinealectomized rat bone marrow to macrophage colony stimulating factor (rGM-CSF) and human recombinant erythropoietin (rEPO), Prog. Brain Res. 91:323–325.PubMedCrossRefGoogle Scholar
  23. Hansson, I., Holmdahl, R., and Mattsson, R., 1992, The pineal hormone melatonin exaggerates development of collagen-induced arthritis in mice, J. Neuroimmunol. 39:23–31.PubMedCrossRefGoogle Scholar
  24. Hiddinga, H.J., Isaak, D.D., and Lewis, R.V., 1994, Enkephalin-containing peptides processed from proenkephalin significantly enhance the antibody-forming cell responses to antigens, J. Immunol. 152:3748–3758.PubMedGoogle Scholar
  25. Hofbauer, L.C. and Heufelder, A.E., 1996, Endocrinology meets immunology: T lymphocytes as novel targets for melatonin, Eur. J. Endocrinol. 134:424–425.PubMedCrossRefGoogle Scholar
  26. Iguchi, H., Kato, H., and Ibayashi, H., 1982, Age-dependent reduction in serum melatonin concentrations in healthy subjects, J. Clin. Endocrinol. Metab. 55:27–32.CrossRefGoogle Scholar
  27. Konakchieva, R., Kyurkchiev, S., Kehayov, I., Taushanova, P., and Kanchev, L., 1995, Selective effect of methoxyndoles on the lymphocyte proliferation and melatonin binding to activated human lymphoid cells, J. Neuroimmunol. 63:125–132.PubMedCrossRefGoogle Scholar
  28. Lissoni, P., Pittalis, S., Barni, S., Rovelli, F., Fumagalli, L., and Maestroni, G.J.-M., 1997a, Regulation of interleukin-2/interleukin-12 interactions by the pineal gland, Int. J. Thymology 5:443–447.Google Scholar
  29. Lissoni, P., Rovelli, F., Brivio, F., Pittalis, S., Maestroni, G.J.M., and Fumagalli, L., 1997b, In vivo study of the modulatory effect of the pineal hormone melatonin on interleukin-12 secretion in response to interleukin-2, Int. J. Thymology 5:482–486.Google Scholar
  30. Lissoni, P., Tisi, E., Barni, S., Ardizzoia, A., Rovelli, F., Rescaldani, R., Ballabio, D, Benenti, G., Angeli, M., Tancini, G., Conti, A., and Maestroni, G.J.M., 1992, Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer, Br. J. Cancer 66:155–158.PubMedCrossRefGoogle Scholar
  31. Maestroni, G., Hertens, E., Galli, P., Conti, A., and Pedrinis, E., 1996, Melatonin-induced T-helper cell hematopoietic cytokines resembling both interleukin-4 and dynorphin, J. Pineal Res. 21:131–139.PubMedCrossRefGoogle Scholar
  32. Maestroni, G.J.M., 1993, The immunoneuroendocrine role of melatonin, J. Pineal Res. 14:1–10.PubMedCrossRefGoogle Scholar
  33. Maestroni, G.J.M., 1998, Kappa-opioid receptors in marrow stroma mediate the hematopoietic effects of melatonin-induced opioid cytokines, Ann. N Y Acad. Sci. 840:411–420.PubMedCrossRefGoogle Scholar
  34. Maestroni, G.J.M. and Conti, A., 1989, Beta-endorphin and dynorphin mimic the circadian immunoenhancing and anti-stress effects of melatonin, Int. J. Immunopharmacol. 11:333–340.PubMedCrossRefGoogle Scholar
  35. Maestroni, G.J.M. and Conti, A., 1990, The pineal neurohormone melatonin stimulates activated CD4+, Thy-1+ cells to release opioid agonist(s) with immunoenhancing and anti-stress properties, J. Neuroimmunol. 28:167–176.PubMedCrossRefGoogle Scholar
  36. Maestroni, G.J.M. and Conti, A., 1991, Anti-stress role of the melatonin-immuno-opioid network. Evidence for a physiological mechanism involving T cell-derived, immunoreactive ß-endorphin and enkephalin binding to thymic opioid receptors, Int. J. Neurosci. 61:289–298.PubMedCrossRefGoogle Scholar
  37. Maestroni, G.J.M. and Conti, A., 1993, Melatonin in relation to the immune system, in: Melatonin. Biosynthesis, Physiological effects and Clinical Applications (H.-S. Yu and R.J. Reiter, eds.), pp. 290–306, CRC Press, Boca Raton.Google Scholar
  38. Maestroni, G.J.M. and Conti, A., 1996, Melatonin in human breast cancer tissue: Association with nuclear grade and estrogen receptor status, Lab. Invest. 75:557–561.PubMedGoogle Scholar
  39. Maestroni, G.J.M., Conti, A., and Lissoni, P., 1994a, Colony-stimulating activity and hematopoietic rescue from cancer chemothereapy compounds are induced by melatonin via endogenous interleukin 4, Cancer Res. 54:4740–4743.PubMedGoogle Scholar
  40. Maestroni, G.J.M., Conti, A., and Pierpaoli, W., 1986, Role of the pineal gland in immunity. Circadian synthesis and release of melatonin modulates the antibody response and antagonize the imunosuppressive effect of corticosterone, J. Neuroimmunol. 13:19–30.PubMedCrossRefGoogle Scholar
  41. Maestroni, G.J.M., Conti, A., and Pierpaoli, W., 1987, Role of the pineal gland in immunity: II. Melatonin enhances the antibody response via an opiatergic mechanism, Clin. Exp. Immunol. 68:384–391.PubMedGoogle Scholar
  42. Maestroni, G.J.M., Covacci, V., and Conti, A., 1994b, Hematopoietic rescue via T-cell-dependent, endogenous GM-CSF by the pineal neurohormone melatonin in tumor bearing mice, Cancer Res. 54:2429–2432.PubMedGoogle Scholar
  43. Maestroni, G.J.M., Flamigni, L., Hertens, E., and Conti, A., 1995, Biochemical and functional characterization of melatonin-induced opioids in spleen and bone marrow T-helper cells, Neuroendocrinol. Lett. 17:145–153.Google Scholar
  44. Maestroni, G.J.M. and Pierpaoli, W., 1981, Pharmacological control of the hormonally modulated immune response, in: Psychoneuroimmunology, vol. I (R. Ader, ed.). pp. 405–425, Academic Press, New York.Google Scholar
  45. Morrey, M.K., McLachlan, J.A., Serkin, C.D., and Bakouche, O., 1994, Activation of human monocytes by the pineal neurohormone melatonin, J. Immunol. 153:2671–2680.PubMedGoogle Scholar
  46. Neri, B., De Leonardis, V., Gemelli, M.T., DiLoro, M., Mottola, A., Ponchietti, R., Raugei, A., and Cini, G., 1998, Melatonin as biological response modifier in cancer patients, Anticancer Res. 18:1329–1332.PubMedGoogle Scholar
  47. Neri, B., Fiorelli, C., Moroni, F., Nicita, G., Paoletti, M.C., Ponchietti, R., Raugei, A., Santoni, G., Trippitelli, A., and Grechi, G., 1994, Modulation of human lymphoblastoid interferon activity by melatonin in metastatic renal cell carcinoma. A phase II study, Cancer 73:3015–3019.PubMedCrossRefGoogle Scholar
  48. Palermo, M.S., Vermeulen, M., and Giordano, M., 1994, Modulation of antibody-dependent cellular cytotoxicity by pineal gland, in: Advances in Pineal Research, vol. 7 (G.J.M. Maestroni, A. Conti, R.J. Reiter, eds.), pp. 143–147, John Libbey, London.Google Scholar
  49. Pioli, C., Caroleo, M.C., Nistico, G., and Doria, G., 1993, Melatonin increases antigen presentation and amplifies specific and non specific signals for T-cell proliferation, Int. J. Immunopharmacol. 15:463–469.PubMedCrossRefGoogle Scholar
  50. Poon, A.M., Liu, Z.M., Pang, C.S., Brown, G.M., and Pang, S.F., 1994, Evidence for a direct action of melatonin on the immune system, Biol. Signals 3:107–117.PubMedCrossRefGoogle Scholar
  51. Wichmann, M., Zellweger, R., De Maso, A., Ayala, A., and Chaudry, I., 1996, Melatonin administration attenuates depressed immune functions trauma-hemorrhage, J. Surg. Res. 63:256–262.PubMedCrossRefGoogle Scholar
  52. Young, M.R.I., Young, M.E., and Kim, K., 1988, Regulation of tumor-induced myelopoiesis and the associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma by prostaglandin E2, Cancer Res. 48:6826–6831.PubMedGoogle Scholar
  53. Yu, H.-S., Tsin, A.T.C., and Reiter, R.J., 1993, Melatonin: History, Biosynthesis, and Assay Methodology, in: Melatonin. Biosynthesis, Physiological Effects, and Clinical Applications (H.-S. Yu and R.J. Reiter, eds.), pp. 1–17, CRC Press, Boca Raton.Google Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • George J. M. Maestroni
    • 1
  1. 1.Istituto Cantonale Di PatologiaCenter for Experimental PathologyLocarnoSwitzerland

Personalised recommendations